Non-small cell lung cancer is the most common type of lung cancer, accounting for 85 percent of all lung cancer diagnoses. To help multidisciplinary cancer care teams better understand and address existing barriers to care, ACCC has embarked on a national initiative to identify and provide guidance on key issues related to the care of patients diagnosed with early-stage IB/IIIA non-small cell lung cancer across different practice settings.
New research suggests there may be a potential role for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with early-stage, resected EGFR mutation-positive non-small cell lung cancer. However, biomarker testing is not currently the standard of care for this patient population. In addition to other ACCC initiatives that address disparities in cancer care, this project will address inequities surrounding care for patients with early-stage non-small cell lung cancer by evaluating the utilization biomarker testing and treatment of patients and identifying ideal care recommendations for this population amid rapidly advancing clinical data.
It will also focus on the nuances of EGFR mutations, the utilization of biomarker testing to identify individual patient eligibility for potential EFGR TKI adjuvant therapy, and the development of efficient, guideline-concordant biomarker testing pathways for this patient population.
For more information on this project, please contact the ACCC Provider Education department.
As precision medicine continues to evolve, understanding the role of biomarker testing in guiding treatment decisions and optimizing treatment strategies through patient navigation and care coordination is critical for providing patient-centered care. This webinar will navigate the complexities of early-stage non-small cell lung cancer (NSCLC) care, offering health care professionals valuable insights on how to better coordinate care and integrate emerging therapies.
In this one-hour event, an expert panel of oncology care professionals discuss ways to identify ideal care recommendations for individuals with Stage IB-IIIA non-small cell lung cancer (NSCLC) amid rapidly advancing clinical data. Explore emerging trends, including considerations for neoadjuvant and/or adjuvant treatment, radiation in patients with early-stage NSCLC, and the role of navigators in care coordination from diagnosis to post-treatment care.
Communities around the globe recognize August 1 as World Lung Cancer Day—a day to commemorate, educate, and support individuals and families impacted by lung cancer. Read highlights on a few ACCC initiatives that are helping cancer care teams better support their patients with this disease.
Lung cancer is the leading cause of cancer death and the second-most common cancer detected in both men and women in the U.S. Lung cancer accounts for nearly 25% of all cancer deaths in this country. According to estimates by the American Cancer Society, 235,760 patients will be diagnosed with lung cancer, and 131,880 patients will die of the disease in 2021.
August 1 marks World Lung Cancer Day. Long at the forefront of teaching multidisciplinary cancer care teams about how to best implement new and evolving lung cancer therapies into their programs and practices, ACCC shares several of its current initiatives to promote optimal lung cancer care delivery.
In this survey of multidisciplinary providers across the US, ACCC assesses the current state of diagnostic, staging, and treatment practices for patients with Stage IB-IIIA non-small cell lung cancer (NSCLC). Read on to learn about the common barriers and potential responses for improving care for patients with early stage NSCLC.
Learn about a new resource developed by expert stakeholders that incorporates evidence-based guidance on best practice in stage IB/IIIA NSCLC. The resource addresses recommendations in four core components: care coordination and patient education, diagnosis and initial management, treatment planning, and survivorship, and can be used by cancer programs to promote ideal care to patients with stage IB/IIIA NSCLC.